798 related articles for article (PubMed ID: 26463870)
21. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada.
Mozessohn L; Cheung MC; Fallahpour S; Gill T; Maloul A; Zhang L; Lau O; Buckstein R
Br J Haematol; 2018 Jun; 181(6):803-815. PubMed ID: 29767427
[TBL] [Abstract][Full Text] [Related]
22. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
23. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
24. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
26. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
27. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
28. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Schiffer M; Zhao J; Johnson A; Lee J; Bewersdorf JP; Zeidan AM
Expert Rev Anticancer Ther; 2021 Sep; 21(9):989-1002. PubMed ID: 33853476
[TBL] [Abstract][Full Text] [Related]
29. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
30. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
[TBL] [Abstract][Full Text] [Related]
32. Azacitidine for the treatment of myelodysplastic syndrome.
Cataldo VD; Cortes J; Quintás-Cardama A
Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
[TBL] [Abstract][Full Text] [Related]
33. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
34. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
Future Oncol; 2022 Nov; 18(36):4017-4029. PubMed ID: 36622291
[TBL] [Abstract][Full Text] [Related]
38. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan AM; Gore SD; Komrokji RS
Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Short NJ; Kantarjian H
Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436
[TBL] [Abstract][Full Text] [Related]
40. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
